On March 16, 2023 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported its financial results for 2022 and provides an update on its product pipeline (Press release, Transgene, MAR 16, 2023, View Source [SID1234628949]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Hedi Ben Brahim, CEO of Transgene, commented: "I am extremely happy with the multiple positive milestones that Transgene has delivered in 2022 and I would like to thank all our employees and partners for their commitment and support. We also are very encouraged by the growing industry interest in therapeutic cancer vaccines and oncolytic viruses that have the potential to become new standards of care for the treatment of solid tumors. This trend backs us in our strategy and validates our technological and medical choices. I am confident that Transgene is at the forefront of helping to realize the potential of these exciting treatment modalities.
"With regard to our therapeutic cancer vaccine pipeline, we presented new Phase I results for TG4050 demonstrating the full clinical and commercial potential of this highly innovative neoantigen vaccine in patients with head and neck cancer. These very encouraging data have led us to start the planning of Phase II trial. Positive data from this Phase II trial could be used for a potential registration of TG4050. For TG4001, our most advanced product, the positive outcome of the interim analysis of the Phase II trial in HPV-positive cancers has allowed us to reduce the total number of patients to be randomized in the ongoing study.
"Turning to the oncolytic virus platform, we have achieved two important milestones. We presented new positive data from the Phase I trial evaluating our oncolytic virus TG6002 administered intravenously, showing in all patients its ability to reach the tumor, multiply and express its payload. The ability to administer our oncolytic viruses intravenously significantly expands the range of solid tumors they can be used to treat and the market opportunity they can access. In addition, we announced the launch of a new oncolytic virus, TG6050. This multi-armed oncolytic virus has been designed to address major solid tumor indications, such as lung cancer, and will begin a Phase I in the months ahead.
"The progress we have made in 2022 has positioned Transgene to deliver multiple major milestones in the next 18 months, including launching potentially registrational trials for our two most advanced therapeutic vaccine candidates, as well as a Phase I study with our high-potential oncolytic virus, TG6050, given by intravenous administration.
"Based on the potential of TG4050, TG4001 and TG6050, I believe that Transgene has a very exciting future and is well positioned to deliver for all of its key stakeholders."
Key achievements in 2022 and expected near-term news flow
Therapeutic Cancer Vaccines
TG4001: Positive result from interim analysis of randomized Phase II trial in HPV-positive anogenital cancers
With TG4001, Transgene aims to bring a new solution to patients with HPV-positive anogenital cancers who currently have very limited second-line treatment options.
In November 2022, Transgene announced that following a prespecified interim analysis of its randomized, Phase II clinical study comparing TG4001 in combination with avelumab vs avelumab alone in patients with HPV16-positive anogenital tumors (NCT: 03260023), the Independent Data Monitoring Committee (IDMC) has recommended the study continue. Based on progression-free survival (PFS) and positive efficacy signals observed in the interim analysis, the trial is now expected to enroll a total of 120 patients compared to the initial forecast of 150 patients.
Transgene anticipates the last patient to be randomized in the trial in the first half of 2024, and final results to be communicated in 2024.
Based on the positive outcome of the interim analysis, we are already working on the initial design of a potentially registrational trial to further confirm the benefit of this therapeutic vaccine.
TG4050: Strong clinical and commercial potential confirmed by initial data from the two ongoing Phase I trials – Transgene is preparing a Phase II trial in head and neck cancers
The personalized therapeutic vaccine TG4050 is intended to extend the remission of patients at high risk of relapse.
In the randomized Phase I trial in head and neck patients, following surgery and radio-chemotherapy, the latest data reported was as of the end of August 2022, when 20 of the 30 planned patients had been randomized.
All 10 evaluable patients who were vaccinated with TG4050 remained stable and in complete response at the cutoff date. This contrasts with the control group where 2 out of the 10 patients, who did not receive the vaccine, have relapsed. Transgene expects treatment start of the last patient in this Phase I trial in the first half of 2023.
In the current Phase I ovarian cancer trial (n=5), one patient treated after an elevation of CA-125 experienced a normalization of CA-125 without clinical progression for nine months until death from an unrelated chronic illness. Another patient was treated upon onset of radiological evidence of relapse and remained stable for 11.4 months. Although enrollment in this trial has been completed, treatment of patients is significantly delayed by the recent registration of PARP inhibitors, extending the time to relapse, which is required before they can receive treatment with TG4050.
Transgene has also produced data on circulating tumor DNA (ctDNA); signals of this increasingly validated surrogate marker of efficacy are particularly encouraging. Combined with the first signs of clinical activity, these results suggest that the individualized TG4050 vaccine has the potential to extend the period of remission, potentially offering a new treatment option for cancer patients.
In the two clinical studies, enrollment has been completed. To date, TG4050 vaccine has been well tolerated and no related Serious Adverse Events have been reported.
The Company is preparing a Phase II trial in head and neck cancers. Positive data from this upcoming trial could be used for a potential registration of TG4050.
Further information on our development plans for TG4050 will be communicated following the presentation of a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (April 2023).
Oncolytic Viruses
TG6002: New data support the potential of intravenous administration of Invir.IO-based oncolytic viruses – Key competitive advantage
Clinical data generated with TG6002, has enabled Transgene to confirm the mechanism of action, competitive advantages and safety of our Invir.IO based oncolytic viruses.
Data generated on 37 patients treated in the Phase I study assessing its intravenous administration (IV) have been presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Congress (September 2022).
These findings support the potential of IV administration of Invir.IO-based oncolytic viruses, extending the use of these therapies to a much broader range of solid tumors. At present the use of oncolytic viruses is limited by their intratumoral administration.
Additional data will be produced from the Phase I program and will be presented at AACR (Free AACR Whitepaper) (April 2023).
BT-001: Positive initial clinical data in monotherapy
In June 2022, Transgene and BioInvent released positive progress and safety data in the ongoing Phase I/IIa trial evaluating BT-001 in patients with solid tumors. The initial data generated in the Part A of the Phase I trial demonstrated that BT-001 alone is well tolerated, with first signs of anti-tumor activity in a hard-to-treat population and confirmed the mechanism of action of BT-001 as a single agent.
A clinical collaboration and supply agreement for KEYTRUDA (pembrolizumab) was signed with MSD (Merck & Co) at the end of June 2022. The Part B of the Phase I trial (in combination with pembrolizumab) is expected to start in the second half of 2023.
TG6050: Novel Invir.IO candidate designed to express IL-12 and be administered IV to enter the clinic
In early 2023, Transgene announced the regulatory approval to initiate a clinical trial of TG6050, a novel oncolytic virus from its Invir.IO platform. This innovative candidate has been designed to express human IL-12, a cytokine known to trigger a potent anti-tumor immune response, and a full-length anti-CTLA4 antibody.
The Delivir trial will evaluate TG6050 in patients with advanced non-small cell lung cancer who have failed treatment with an anti-PD1 agent.
The first patient will be enrolled in the first half of 2023. With TG6050, Transgene seeks to capitalize on the attractiveness of IL-12, while limiting exposure to its systemic toxicity through the selectivity of Invir.IO oncolytic viruses.
Collaboration with AstraZeneca
The research collaboration with AstraZeneca on viruses derived from the Invir.IO platform continues to move forward.
Key scientific advisors
In March 2023, Transgene appointed Dr. John C. Bell and Dr. Pedro Romero as key scientific advisors. These key opinion leaders in cancer immunotherapy bring considerable expertise to Transgene.
Summary of key ongoing clinical trials
TG4001
+ avelumab
Phase II
NCT03260023
Targets: HPV16 E6 and E7 oncoproteins
Recurrent/metastatic anogenital HPV16-positive — 1st (patients ineligible for chemotherapy) and 2nd lines
ü Randomized Phase II trial comparing the combination of TG4001 with avelumab versus avelumab alone
ü Ongoing patient enrollment in Europe (France and Spain) and in the USA
ü Positive result of interim analysis, allowing trial to continue. Total number of patients to be randomized reduced from 150 to 120
Ü Last patient expected to be randomized in H1 2024
Ü Final results to be communicated in 2024
Ü Registration targeting trial being prepared
myvac
TG4050
Phase I
NCT04183166
Targets: tumor neoantigens
ü Codeveloped with NEC
ü Positive initial data demonstrating the immunogenicity of the vaccine as well as first signs of clinical activity
Ü Additional data expected in H1 2023 (AACR) (Free AACR Whitepaper)
HPV-negative head and neck cancers — after surgery and adjuvant therapy
ü Trial ongoing in the UK and in France
ü Patient enrollment completed
ü Treatment start of last patient expected in H1 2023
Ü Preparation of registration targeting Phase II trial
TG4050
Phase I
NCT03839524
Ovarian cancer — after surgery and first-line chemotherapy
ü Trial ongoing in the USA and in France
ü Patient enrollment completed
TG6002
Phase I/IIa
NCT03724071
Payload: FCU1 for the local production of a 5-FU chemotherapy
Ü Additional data to be presented at AACR (Free AACR Whitepaper) (April 2023)
Advanced gastro-intestinal cancer — Intravenous (IV) administration
ü Multicenter trial – France, Belgium and Spain
ü Data confirming the potential of the IV administration presented at ESMO (Free ESMO Whitepaper) 2022 (Sept. 2022)
ü Patient enrollment completed in Phase I part
TG6002
Phase I/IIa
NCT04194034
Colorectal cancer with liver metastasis — Intrahepatic artery (IHA) administration
ü Multicenter trial – UK and France
ü Patient enrollment completed in Phase I part
Invir.IO
BT-001
Phase I/IIa
NCT04725331
Payload: anti-CTLA4 antibody and GM-CSF cytokine
Solid tumors
ü Co-development with BioInvent
ü Collaboration agreement with MSD, supplying pembrolizumab for the trial
ü Trial ongoing in France, Belgium and approved in the USA
ü Initial data showing safety and first signs of clinical activity
Ü Part A data to be communicated in H1 2023
Ü Start of part B of the Phase I trial in H2 2023
Invir.IO
TG6050
Phase I (Delivir)
Payload: interleukin-12 (IL-12) and anti-CTLA4 antibody
Non-Small Cell Lung Cancer (NSCLC) – Intravenous (IV) administration
ü Promising preclinical results to be presented at AACR (Free AACR Whitepaper) (April 2023)
ü Multicenter trial
Ü First patient to be enrolled in H1 2023
Key financials for 2022
– Operating income of €10.3 million in 2022, compared to €17.4 million in 2021.
R&D services for third parties amounted to €3.1 million in 2022 (€10.0 million in 2021), mainly due to the collaboration with AstraZeneca. In 2021, AstraZeneca exercised the first license option for an oncolytic virus developed by Transgene. This option exercise led to Transgene receiving a €7.1 million payment.
Research tax credit amounted to €6.8 million in 2022 (€7.0 million in 2021).
– Net operating expenses of €40.2 million in 2022, compared to €40.9 million in 2021.
R&D expenses were €32.2 million in 2022 (€32.9 million in 2021).
General and administrative expenses amounted to €7.9 million in 2022 (€7.4 million in 2021).
– Financial loss of €2.9 million in 2022, compared to an income of €4.0 million in 2021.
– Net loss of €32.8 million in 2022, compared to a net loss of €19.5 million in 2021.
– Net cash burn of €22.8 million in 2022, compared to €10.0 million in 2021 (excluding capital increase).
– Cash available at year-end 2022: €26.8 million, compared to €49.6 million at the end of 2021. In addition, Transgene still holds Tasly BioPharmaceuticals shares reevaluated at €14.3 million at the end of December 2022. The Company is expecting to sell its shareholding in Tasly BioPharmaceuticals in mid-2023.
– Transgene has a financial visibility until early 2024.
The financial statements for 2022 as well as management’s discussion and analysis are attached to this press release (Appendices A and B).
The Board of Directors of Transgene met on March 16, 2023, under the chairmanship of Dr. Alessandro Riva and closed the 2022 financial statements. Audit procedures have been performed by the statutory auditors and the delivery of the auditors’ report is ongoing.